1-Hydroxy-4-aminoadamantane, also known as memantine, is a chemical compound characterized by its adamantane structure, which consists of a fused three-dimensional carbon framework. This compound features a hydroxyl group (-OH) and an amino group (-NH2) attached to the adamantane core, contributing to its pharmacological properties. Memantine is primarily recognized for its role as an NMDA receptor antagonist, which is significant in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. The compound exhibits moderate lipophilicity, allowing it to cross the blood-brain barrier effectively. Its mechanism of action involves the modulation of glutamatergic neurotransmission, which is crucial for cognitive functions. Memantine is generally well-tolerated, with a side effect profile that includes dizziness, headache, and constipation. The substance is typically administered in oral form and is available in various formulations, including extended-release options. Overall, 1-hydroxy-4-aminoadamantane represents an important therapeutic agent in managing cognitive decline associated with Alzheimer's disease.

1-Hydroxy-4-aminoadamantane

75375-89-2: 1-Hydroxy-4-aminoadamantane, also known as memantine, is a chemical compound characterized by its adamantane structure, which consists of a fused three-dimensional carbon framework. This compound features a hydroxyl group (-OH) and an amino group (-NH2) attached to the adamantane core, contributing to its pharmacological properties. Memantine is primarily recognized for its role as an NMDA receptor antagonist, which is significant in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. The compound exhibits moderate lipophilicity, allowing it to cross the blood-brain barrier effectively. Its mechanism of action involves the modulation of glutamatergic neurotransmission, which is crucial for cognitive functions. Memantine is generally well-tolerated, with a side effect profile that includes dizziness, headache, and constipation. The substance is typically administered in oral form and is available in various formulations, including extended-release options. Overall, 1-hydroxy-4-aminoadamantane represents an important therapeutic agent in managing cognitive decline associated with Alzheimer's disease.

CAS 75375-89-2

1-Hydroxy-4-aminoadamantane

4-Aminotricyclo[3.3.1.13,7]decan-1-ol

Ref: IN-DA00G2DB